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Abstract: The streptococcal preparation, OK.432, with predomi-
nant host-mediated mode of action, was studied. By giving OK-432 to
mice intraperitoneally prior to transplantation of Ehrlich carcinoma,
a host-mediated action to increase life-span was clearly confirmed.
Pretreatment with OK-432 was also effective against the development
of Rauscher leukemia. The host-mediated action of OK-432 varied
with the interval between its pretreatment and the inoculation of
tumor cells. The effect was most marked when the transplant was
performed immediatedly after the pretreatment, and became less
marked when the transplant was made one week and two weeks after
pretreatment. The host-mediated action can be observed even with a
single dose of pretreatment, and becomes more potent as pretreatment
was given repeatedly. The host-mediated action was weakened by
concomitant pretreatment with cyclophosphamide or roentgen irradia-
tion, and the mechanisms of such action was supposed to be associated
with the function of the reticulo-endothelial system.
It has been gradually shown that OK432, (1,2) a streptococcal prepara-
tion developed in Japan, has a specific mode of action. We have gone a step
further towards the treatment of malignant tumors, especially leukemia to
study combination therapy of OK-432 with the so-called anti-cancer agents
(4, 5), and shown that combination therapy produces remarkable effect. In
these studies, we noted the fact that the agent hardly showed a cytotoxic
activity on tumor cells in vitro while it was moderately effective' on tumor-
bearing mice, and that the response of each patient to OK-432 was slightly
dose-related in clinical use. The idea to use a streptococcal preparation came
primarily from the fact that regression of malignant tumors was seen during
the attack of serious infection by hemolytic streptococci (6, 7, 8) ; it appears
that OK-432 may possess a host-mediated action that has not been found with
other anti-cancer agents. Our present report concerns the results obtained so
far from our studies as to the presence or absence of host-mediated action and
its mechanism.
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MATERIALS AND METHODS
OK-432: This agent was prepared from a low-virulent strain Su of strepto-
coccus haemolyticus established by OKAMOTO et al. (1, 2). One KE (Klinische
Einheit, i. e., unit) contains O. I mg of prepared hemolytic streptococci in dry
weight.
Animal: Six week-old male ICR mice were employed for Ehrlich carci-
noma, and also six week-old male CB mice for Rauscher leukemia.
Ehrlich ascitic tumor: Six to seven days after intraperitoneal (i. p.) trans-
plantation, tumor cells were harvested and washed once with ice cold phosphate-
buffered saline (PBS) solution, and subsequently the cell number was adjusted
to 101 , 102 , 103 or 104 in 0.1 ml, which was inoculated i. p.. As for intravenous
(i. v.) inoculation, tumor cells were washed 3 times in order to avoid aggregation
of tumor cells and 2x 106 cells in O. 1 ml was inoculated into the tail vein.
Rucher leukemia: Mice were inoculated with a dose of Rauscher leukemia
viruses (RLV) in 0.2 ml of the supernatant containing 20% spleen homogenate.
Pretreatment with OK-432: Pretreatment was made i. p. or subcutaneously
(s. c.) with IKE/mouse of OK-432 for various periods prior to the tumor trans-
plantation as indicated in the results. To control group 0.1 ml of isotonic saline
solution was given for the same periods as experimental groups.
India ink clearance: To three groups consisted of 12 mice in each group,
1KE/mouse of OK.432 alone or 0.5 mg/kg, body weight, of Mitomycin C
(MMC) combined were administered for 10 days. On the days 1 and 10 after
completion of the treatment mice were sacrificed, and India ink clearance was
tested according to the method reported by WATANUKI (9).
Hemololytic plaque forming cell (HPFC) count: This was done according to
CUNNINGHAM (10). Treatment with OK.432 was made 24 hr before the i. p. im-
munization with sheep red blood cells, and HPFC count was studied five days
after the immunization.
RESULTS
1. Effects ofpretreatment on Ehlrich carcinoma.
OK-432, Cyclophosphamide (CPA) or MMC was given i. p. for 5 days
and Bleomycin once for all, and 5 days later 2 X 106 of tumor cells were in-
oculated i. v. via the tail vein. Through observation of pulmonary metastasis
two weeks after inoculation, pretreatment with OK-432 was found to have
inhibited the metastasis, in contrast to pretreatment with other anticancer
agents, such as CPA, MMC and Bleomycin, which enhanced the metastasis
(Fig. 1).
Action of OK-432 was studied further by changing the interval between
pretreatment and i. v. transplantation of Ehlrich carcinoma in three ways
(Fig. 2); on the following day and one and two weeks after pretreatment.
The group receiving i. v. inoculation on the next day of pretreatment showed
an excellent 50-day-survival rate as compared with the control group. Pro-
longation of life-span to some degree, but less than the above, was also noted
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Fig. 1. Effect of pretreatment with some anti-cancer agents on blood-
born pulmonary metastasis
To each group consisting of 12 mice, OK-432, 60 mg/kg of CPA or
1mg/kg of MMC was administered for 5 days and 20mg/kg of Bleomycin
once for all.
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Fig. 2. Effect of pretreatment with OK·432 on i. v. inoculated Ehrlich
carcinoma
To each group consisting of 15 to 16 mice, OK-432 was given for 7 days.
On the following day and I and 2 weeks later, 2 X 106 of tumor cells were
inoculated i. v. Vertical lines indicate percent of surviving fraction.
3
Kimura et al.: Studies on the host-mediated action of the streptococcal
Produced by The Berkeley Electronic Press, 1974
426 I. KIMURA, T. ONOSHI, S. YASUHARA, T. WATANABE, M. SUGIYAMA and K. HIRAKI
in the group that was inoculated one week later. In the group transplanted
two weeks after pretreatment, the survival rate was similar to that of control
without showing any life prolongation.
Subsequently, the effect of pretreatment with OK-432 injected i. p. on
Ehrlich carcinoma inoculated also i. p. was studied (Fig. 3). Although i. p.
transplantation of tumor cells as many as 106 was not affected by pretreat-
ment with OK-432, influence of pretreatment was noted when 104 cells were
inoculated i. p.. This tendency for prolonging life-span with pretreatment
became marked as the inoculation size of cells was decreased in the order of
103 , 102 and 10 1, suggesting the presence of a host-mediated effect on the
i. p. transplantation as in the case of i. v.. A similar tendency was also
noted in the s. c. pretreatment with OK-432. The influence of a repeated
pretreatment was studied by examining the survival rate in three groups of
mice that were treated for one, 7 and 14 consecutive days, followed by i. p.
inoculation of the tumor cells. The life-prolongation was appreciable even
with pretreatment for one day, and the effect was increased as pretreatment
was carried out repeatedly (Fig. 4).
The effects of pretreatment combined with OK-432 and CPA prior to the
i. v. transplantation of tumor cells were then studied (Fig. 5). With OK-432
alone the same results as described above were obtained again, and with
CPA alone survival shorter than the controls was noted. In contrast to pre-
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Fig. 3. Effect of pretreatment with OK-432 on i. p. inoculated Ehrlich
carcinoma
To each group consisting of 10 mice, the same pretreatment as Fig. 2 was
done. Two days later, 101 , 102 , 108 or 104 of tum'or cells were inoculated i. p.,
followed by survival.
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Fig. 4. Dose frequency of pretreatment with OK-432 and effect on Ehrlich
carcinoma
Each group consisting of 10 mice was pretreated i. p. with OK-432 for one,
7 and 14 days. Two days later 104 of tumor cells were inoculated i. p., followed
by survival.
treatment with OK-432 which produced favorable prolongation of life, CPA
decreased the effect of OK-432 when used concomitantly.
The same results were also obtained with whole-body irradiation; the
irradiation weakened the action of OK-432, and simultaneously, the effect of
irradiation on mice was somewhat lessened by the .use of OK-432. It was
shown, therefore, that the host-mediated action of OK-432 can hardly be
exerted under immuno-suppressed conditions, raising an important problem
in cancer chemotherapy.
2. Effects of pretreatment on Rauscher leukemia.
When OK-432 was administered prior to the inoculation of RLV, an
inhibition was apparently indicated by spleen weights and peripheral nucleated
cell counts, and similar results were also obtained when OK-432 was given
before as well as after the inoculation, whereas the effects of OK-432, when
given after the inoculation, did not differ much from the controls (Fig. 6).
In other words, the influence of the host-mediated action of OK-432 was
noted at the onset of Rauscher leukemia. In addition, it was demonstrated
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Fig. 5. Effect of pretreatment with OK-432 and CPA or whole body
X-ray irradiation on i. v. inoculated Ehrlich carcinoma
Pretreatment was started at day 9 prior to i. v. inoculation of 2 X 106 of
tumor cells. OK-432 for 7 days, CPA for 3 days and whole body X-ray
irradiation once for all.
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Fig. 6. Effect of OK-432 on Rauscher leukemia
Spleen weight and peripheral nucleated cell counts were studied 3
weeks after inoculation.
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Fig. 7. Effect of pretreatment with OK-432 on survival of Rauscher
leukemia mice
To each group consisting of 12 mice, OK-432 was given i. p. or s.c. for
7 days. One week later, RLV was inocuated i. p., followed by survival.
that pretreatment with OK-432 exerted some influence on the survival in
Rauscher leukemic mice; this is more predominant when it is pretreated, i. p.
more than when done s. c. (Fig. 7).
3. The mechanism of host-mediated action.
This was studied based on the function of reticulo-endothelial system
(Fig. 8). The results indicated that reticulo-endotherial system function was
enhanced by the administration of OK-432, whereas the combined use of OK-
432 with MMC somewhat lessened the the diminution of the function. By
studying the effect of OK-432 on the antibody-forming capacity by means of
the HPFC count, OK-432 showed a slight tendency, not significant, to in-
crease HPFC in some cases (Table I).
K
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Fig. 8. Effect of OK-432 and/or MMC on India ink clearance
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TABLE 1 EFFECT OF OK-432 ON ANTIBODY-FORMING CELLS IN SPLEEN.
Treatment No. of mice total spleen HPFC/106 spleen cells HPFC/spleenstudied cells (x 106 ) (x 104 )
control 5 144 (l1O~ 165) 1271 (968~2067) 18.1 (15.0~26.91
OK-432 O. 5kE 5 168 (l15~220) 1479 (982~2337) 24.1 (13. 8~31. 2)
JK-432 5kE 5 191 (l70~21O) 1135 (753~ 1555) 21. 5 (14. 7~30. 3)
DISCUSSION
A streptococcal preparation, OK-432, developed by OKAMOTO et al. (1,2)
was prepared from the fact that regression of malignant tumors had often
been seen during the attack of serious infections (6, 7, 8). As stated above,
OK-432 is unique in its pharmacological status and it has a mode of action
that is rather difficult to elucidate only in terms of its direct effect on tumor
cells in contrast to the conventional series of anti-tumor agents. In studying
its influence on the host, apparent life-prolonging effects were observed in
mice with transplanted tumors when it was given i. p. or s. c. as a pretreat-
ment, indicating the presence of host-mediated action. It was shown that
this action could be seen even with a single dose and increased as the medica-
tion was given repeatedly, maintaining a residual effect decreasing gradually
even at about two weeks after withdrawal of medication. A combined use of
CPA with OK-432 at pretreatment weakened the host-mediated action and
similar results were also obtained by roentgen irradiation. Furthermore,
OK-432, when used prior to inoculation of RLV, was found effective against
the development of leukemia.
Trigger mechanisms for such effects were revealed partially to the
extent that OK-432 stimulated the function of the reticulo-endothelial system
but hardly influenced HPFC when tested to observe antibody forming capa-
city. This indicated that OK-432 possesses a hostmediated anti-tumor action,
even though there remains a problem as to whether or not the action has a
specific reaction to immunological mechanism.
Systemic and topical administration are recommended as to the applica-
tion of this drug on man, and KUROKAWA et at. (11) described their clinical
trial with OK-432 alone in detail especially on the patients with carcinoma.
We also experienced (3) a clinical trial on leukemia patients with OK-432
alone. As there was a certain limit of effects for using OK-432 alone, espe-
cially given systemically, we attempted (4, 5) a combined use of OK-432
with other anti-cancer agents, and succeeded in obtaining favorable effects.
HATTORI et al. (12) also obtained similar combined effects by the topical use
of OK-432 with systemic use of MMC. As indicated in our experimental
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studies (5), the best results were obtained when both OK-432 and anti-cancer
agents were given i. p., and OGAWA et ale (13) also noted its effectiveness in
cancerous pleurisy by infusing it intrathoracically. These facts indicate a
possibility of the action of OK-432 through its dtrect contact with tumor
cells. On the other hand, relationship hardly observed between the response
to OK-432 and the dose administered in clinical use (3, 11). In addition, the
effect of OK-432, when used experimentally, is produced more readily in in
vivo than in in vitro. These facts lead us to postulate the presence of a mode
of action other than a direct action and indicate that many other problems
exist further with regard to the mechanism of action of OK-432.
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